Css LLC Mirati Therapeutics, Inc. Call Options Transaction History

Css LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $419,900 - $623,800	10,000 New	10,000 $587,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $178,500 - $260,100	3,000 New	3,000 $210,000
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $1.16 Million - $1.67 Million	-8,800 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $409,603 - $550,095	3,100 Added 54.39%	8,800 $1.56 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $810,491 - $1.13 Million	-5,100 Reduced 47.22%	5,700 $977,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $696,815 - $1.03 Million	4,300 Added 66.15%	10,800 $2.37 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $736,190 - $1.09 Million	6,500 New	6,500 $1.08 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $1.73 Million - $2.89 Million	-24,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $160,494 - $267,283	2,300 Added 10.6%	24,000 $1.85 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $1.54 Million - $2.8 Million	21,700 New	21,700 $2.8 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.